The battle for the $100 billion obesity drug market just got personal. Novo Nordisk — maker of Ozempic and Wegovy — is suing Eli Lilly over Zepbound and Mounjaro ads, accusing the company of "deceptive advertising" that cherry-picks outdated doses to make its drugs look superior. The lawsuit landed in New Jersey federal court on July 21, and Novo escalated Friday by seeking a preliminary injunction to pull the ads immediately. Meanwhile, Lilly fired back with its own...